{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:45:40Z","timestamp":1779889540118,"version":"3.53.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00277-024-05993-5","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T09:03:21Z","timestamp":1726045401000},"page":"4449-4457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Initial US tertiary health care system experience using caplacizumab in patients with immune thrombotic thrombocytopenic purpura"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7246-4486","authenticated-orcid":false,"given":"Jennifer M.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alesia","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Chibisov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Then","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico M.","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E.","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"5993_CR1","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/35097008","volume":"413","author":"GG Levy","year":"2001","unstructured":"Levy GG, Nichols WC, Lian EC et al (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488\u2013494. https:\/\/doi.org\/10.1038\/35097008","journal-title":"Nature"},{"key":"5993_CR2","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1182\/blood-2014-11-551580","volume":"125","author":"FA Sayani","year":"2015","unstructured":"Sayani FA, Abrams CS (2015) How I treat refractory thrombotic thrombocytopenic purpura. Blood 125:3860\u20133867. https:\/\/doi.org\/10.1182\/blood-2014-11-551580","journal-title":"Blood"},{"key":"5993_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","volume":"130","author":"JE Sadler","year":"2017","unstructured":"Sadler JE (2017) Pathophysiology of thrombotic thrombocytopenic purpura. Blood 130:1181\u20131188. https:\/\/doi.org\/10.1182\/blood-2017-04-636431","journal-title":"Blood"},{"key":"5993_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJM199108083250604","volume":"325","author":"GA Rock","year":"1991","unstructured":"Rock GA, Shumak KH, Buskard NA et al (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic Thrombocytopenic Purpura. N Engl J Med 325:393\u2013397. https:\/\/doi.org\/10.1056\/NEJM199108083250604","journal-title":"N Engl J Med"},{"key":"5993_CR5","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/ajh.23455","volume":"88","author":"S Chaturvedi","year":"2013","unstructured":"Chaturvedi S, Carcioppolo D, Zhang L, McCrae KR (2013) Management and outcomes for patients with TTP: analysis of 100 cases at a single institution. Am J Hematol 88:560\u2013565. https:\/\/doi.org\/10.1002\/ajh.23455","journal-title":"Am J Hematol"},{"key":"5993_CR6","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","volume":"1","author":"EE Page","year":"2017","unstructured":"Page EE, Kremer Hovinga JA, Terrell DR et al (2017) Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv 1:590\u2013600. https:\/\/doi.org\/10.1182\/bloodadvances.2017005124","journal-title":"Blood Adv"},{"key":"5993_CR7","unstructured":"Research C for, DE (2019) and FDA approved caplacizumab-yhdp. FDA"},{"key":"5993_CR8","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Scully M, Kremer Hovinga JA et al (2016) Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 374:511\u2013522. https:\/\/doi.org\/10.1056\/NEJMoa1505533","journal-title":"N Engl J Med"},{"key":"5993_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully M, Cataland SR, Peyvandi F et al (2019) Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 380:335\u2013346. https:\/\/doi.org\/10.1056\/NEJMoa1806311","journal-title":"N Engl J Med"},{"key":"5993_CR10","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1182\/blood.2020007599","volume":"137","author":"T Dutt","year":"2021","unstructured":"Dutt T, Shaw RJ, Stubbs M et al (2021) Real-world experience with caplacizumab in the management of acute TTP. Blood 137:1731\u20131740. https:\/\/doi.org\/10.1182\/blood.2020007599","journal-title":"Blood"},{"key":"5993_CR11","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","volume":"4","author":"LA V\u00f6lker","year":"2020","unstructured":"V\u00f6lker LA, Kaufeld J, Miesbach W et al (2020) Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Adv 4:3085\u20133092. https:\/\/doi.org\/10.1182\/bloodadvances.2020001973","journal-title":"Blood Adv"},{"key":"5993_CR12","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.1182\/bloodadvances.2022008028","volume":"6","author":"CP Izquierdo","year":"2022","unstructured":"Izquierdo CP, Mingot-Castellano ME, Fuentes AEK et al (2022) Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura. Blood Adv 6:6219\u20136227. https:\/\/doi.org\/10.1182\/bloodadvances.2022008028","journal-title":"Blood Adv"},{"key":"5993_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1182\/blood.2020008021","volume":"137","author":"P Coppo","year":"2021","unstructured":"Coppo P, Bubenheim M, Azoulay E et al (2021) A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood 137:733\u2013742. https:\/\/doi.org\/10.1182\/blood.2020008021","journal-title":"Blood"},{"key":"5993_CR14","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.3390\/jcm10153418","volume":"10","author":"CN Logothetis","year":"2021","unstructured":"Logothetis CN, Patel A, Eatrides J et al (2021) Post approval experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a single Institution. J Clin Med 10:3418. https:\/\/doi.org\/10.3390\/jcm10153418","journal-title":"J Clin Med"},{"key":"5993_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","volume":"158","author":"M Scully","year":"2012","unstructured":"Scully M, Hunt BJ, Benjamin S et al (2012) Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 158:323\u2013335. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09167.x","journal-title":"Br J Haematol"},{"key":"5993_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","volume":"129","author":"K Kokame","year":"2005","unstructured":"Kokame K, Nobe Y, Kokubo Y et al (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129:93\u2013100. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05420.x","journal-title":"Br J Haematol"},{"key":"5993_CR17","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","volume":"4","author":"PK Bendapudi","year":"2017","unstructured":"Bendapudi PK, Hurwitz S, Fry A et al (2017) Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol 4:e157\u2013e164. https:\/\/doi.org\/10.1016\/S2352-3026(17)30026-1","journal-title":"Lancet Haematol"},{"key":"5993_CR18","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.2020009150","volume":"137","author":"A Cuker","year":"2021","unstructured":"Cuker A, Cataland SR, Coppo P et al (2021) Redefining outcomes in immune TTP: an international working group consensus report. Blood 137:1855\u20131861. https:\/\/doi.org\/10.1182\/blood.2020009150","journal-title":"Blood"},{"key":"5993_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jth.13571","volume":"15","author":"M Scully","year":"2017","unstructured":"Scully M, Cataland S, Coppo P et al (2017) Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost JTH 15:312\u2013322. https:\/\/doi.org\/10.1111\/jth.13571","journal-title":"J Thromb Haemost JTH"},{"key":"5993_CR20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jtha.2022.11.010","volume":"21","author":"LA V\u00f6lker","year":"2023","unstructured":"V\u00f6lker LA, Kaufeld J, Balduin G et al (2023) Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura. J Thromb Haemost JTH 21:559\u2013572. https:\/\/doi.org\/10.1016\/j.jtha.2022.11.010","journal-title":"J Thromb Haemost JTH"},{"key":"5993_CR21","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/jth.15010","volume":"18","author":"XL Zheng","year":"2020","unstructured":"Zheng XL, Vesely SK, Cataland SR et al (2020) ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost JTH 18:2496\u20132502. https:\/\/doi.org\/10.1111\/jth.15010","journal-title":"J Thromb Haemost JTH"},{"key":"5993_CR22","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1111\/jth.15006","volume":"18","author":"XL Zheng","year":"2020","unstructured":"Zheng XL, Vesely SK, Cataland SR et al (2020) ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost JTH 18:2486\u20132495. https:\/\/doi.org\/10.1111\/jth.15006","journal-title":"J Thromb Haemost JTH"},{"key":"5993_CR23","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1182\/bloodadvances.2022008443","volume":"7","author":"M Djulbegovic","year":"2023","unstructured":"Djulbegovic M, Tong J, Xu A et al (2023) Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. Blood Adv 7:2132\u20132142. https:\/\/doi.org\/10.1182\/bloodadvances.2022008443","journal-title":"Blood Adv"},{"key":"5993_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ajh.2830240402","volume":"24","author":"JB Blitzer","year":"1987","unstructured":"Blitzer JB, Granfortuna JM, Gottlieb AJ et al (1987) Thrombotic thrombocytopenic purpura: treatment with plasmapheresis. Am J Hematol 24:329\u2013339. https:\/\/doi.org\/10.1002\/ajh.2830240402","journal-title":"Am J Hematol"},{"key":"5993_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/jca.2920060305","volume":"6","author":"AW Roberts","year":"1991","unstructured":"Roberts AW, Gillett EA, Fleming SJ (1991) Hemolytic uremic syndrome\/thrombotic thrombocytopenic purpura: outcome with plasma exchange. J Clin Apheresis 6:150\u2013154. https:\/\/doi.org\/10.1002\/jca.2920060305","journal-title":"J Clin Apheresis"},{"key":"5993_CR26","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/archinte.1992.00400160089017","volume":"152","author":"PT Onundarson","year":"1992","unstructured":"Onundarson PT, Rowe JM, Heal JM, Francis CW (1992) Response to plasma exchange and splenectomy in thrombotic thrombocytopenic Purpura: a 10-Year experience at a single Institution. Arch Intern Med 152:791\u2013796. https:\/\/doi.org\/10.1001\/archinte.1992.00400160089017","journal-title":"Arch Intern Med"},{"key":"5993_CR27","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/bloodadvances.2020001834","volume":"5","author":"F Peyvandi","year":"2021","unstructured":"Peyvandi F, Cataland S, Scully M et al (2021) Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Adv 5:2137\u20132141. https:\/\/doi.org\/10.1182\/bloodadvances.2020001834","journal-title":"Blood Adv"},{"key":"5993_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-017-2264-7","volume":"106","author":"M Matsumoto","year":"2017","unstructured":"Matsumoto M, Fujimura Y, Wada H et al (2017) Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. Int J Hematol 106:3\u201315. https:\/\/doi.org\/10.1007\/s12185-017-2264-7","journal-title":"Int J Hematol"},{"key":"5993_CR29","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1111\/trf.17111","volume":"62","author":"M Jim\u00e9nez","year":"2022","unstructured":"Jim\u00e9nez M, Bobillo S, Pons V et al (2022) Real-world data with the use of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura: a single-center with homogeneous treatment experience. Transfus (Paris) 62:2363\u20132369. https:\/\/doi.org\/10.1111\/trf.17111","journal-title":"Transfus (Paris)"},{"key":"5993_CR30","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1182\/blood.2020006052","volume":"137","author":"G Goshua","year":"2021","unstructured":"Goshua G, Sinha P, Hendrickson JE et al (2021) Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 137:969\u2013976. https:\/\/doi.org\/10.1182\/blood.2020006052","journal-title":"Blood"},{"key":"5993_CR31","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1182\/blood.2020009250","volume":"137","author":"S Chaturvedi","year":"2021","unstructured":"Chaturvedi S (2021) Counting the cost of caplacizumab. Blood 137:871\u2013872. https:\/\/doi.org\/10.1182\/blood.2020009250","journal-title":"Blood"},{"key":"5993_CR32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1182\/blood.2023019663","volume":"142","author":"S Chaturvedi","year":"2023","unstructured":"Chaturvedi S, Yu J, Brown J et al (2023) Silent cerebral infarction during immune TTP remission: prevalence, predictors, and impact on cognition. Blood 142:325\u2013335. https:\/\/doi.org\/10.1182\/blood.2023019663","journal-title":"Blood"},{"key":"5993_CR33","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","volume":"122","author":"CC Deford","year":"2013","unstructured":"Deford CC, Reese JA, Schwartz LH et al (2013) Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood 122:2023\u20132029. https:\/\/doi.org\/10.1182\/blood-2013-04-496752","journal-title":"Blood"},{"key":"5993_CR34","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/ajh.24060","volume":"90","author":"B Han","year":"2015","unstructured":"Han B, Page EE, Stewart LM et al (2015) Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. Am J Hematol 90:709\u2013714. https:\/\/doi.org\/10.1002\/ajh.24060","journal-title":"Am J Hematol"},{"key":"5993_CR35","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1182\/bloodadvances.2020004169","volume":"6","author":"S Sukumar","year":"2022","unstructured":"Sukumar S, Brodsky M, Hussain S et al (2022) Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission. Blood Adv 6:1264\u20131270. https:\/\/doi.org\/10.1182\/bloodadvances.2020004169","journal-title":"Blood Adv"},{"key":"5993_CR36","doi-asserted-by":"publisher","unstructured":"George JN (2018) TTP: long-term outcomes following recovery. Hematology 2018:548\u2013552. https:\/\/doi.org\/10.1182\/asheducation-2018.1.548","DOI":"10.1182\/asheducation-2018.1.548"},{"key":"5993_CR37","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/jth.15637","volume":"20","author":"L K\u00fchne","year":"2022","unstructured":"K\u00fchne L, Kaufeld J, V\u00f6lker LA et al (2022) Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura. J Thromb Haemost JTH 20:951\u2013960. https:\/\/doi.org\/10.1111\/jth.15637","journal-title":"J Thromb Haemost JTH"},{"key":"5993_CR38","doi-asserted-by":"publisher","first-page":"103682","DOI":"10.1016\/j.transci.2023.103682","volume":"62","author":"R Sarode","year":"2023","unstructured":"Sarode R (2023) Thrombotic thrombocytopenic purpura in caplacizumab era - an individualized approach. Transfus Apher Sci off J World Apher Assoc off J Eur Soc Haemapheresis 62:103682. https:\/\/doi.org\/10.1016\/j.transci.2023.103682","journal-title":"Transfus Apher Sci off J World Apher Assoc off J Eur Soc Haemapheresis"},{"key":"5993_CR39","doi-asserted-by":"publisher","unstructured":"K\u00fchne L, Knoebl P, Eller K et al (2024) Management of Immune Thrombotic Thrombocytopenic Purpura without therapeutic plasma exchange. https:\/\/doi.org\/10.1182\/blood.2023023780. Blood blood.2023023780","DOI":"10.1182\/blood.2023023780"},{"key":"5993_CR40","unstructured":"Study Details | Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05468320. Accessed 4 Jul 2024"},{"key":"5993_CR41","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1111\/jth.15363","volume":"19","author":"J Schofield","year":"2021","unstructured":"Schofield J, Shaw RJ, Lester W et al (2021) Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab. J Thromb Haemost JTH 19:1922\u20131925. https:\/\/doi.org\/10.1111\/jth.15363","journal-title":"J Thromb Haemost JTH"},{"key":"5993_CR42","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1080\/09537104.2021.1922883","volume":"33","author":"K Ditzel","year":"2022","unstructured":"Ditzel K, Mons DJ, Fijnheer R (2022) Fatal cerebral hemorrhage in a patient with thrombotic thrombocytopenic purpura with a normal platelet count during treatment with caplacizumab. Platelets 33:484\u2013485. https:\/\/doi.org\/10.1080\/09537104.2021.1922883","journal-title":"Platelets"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05993-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05993-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05993-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T01:05:39Z","timestamp":1730855139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05993-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["5993"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05993-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"11 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}